Crane NXT heads into its Q1 2026 earnings call — confirmed for May 7 — with short sellers at their most aggressive position in at least six weeks and the stock down 5.8% year-to-date after a brief recovery from April lows.
Short interest is the defining setup here. At 11% of free float, the short position is not just elevated — it has been climbing steadily for five weeks. From roughly 6.0 million shares in late March, estimated shorts have grown to 6.34 million, a rise of about 5.5% over the past month. The borrow market tells the same story in a different register: availability has tightened meaningfully, with utilisation now at 37.6%, approaching its 52-week high of 40.4%. The ORTEX short score has settled at 70.6, ranking CXT in the bottom 3rd percentile of the universe for short score. Days to cover of 13.2 days reinforces how difficult a rapid exit would be for the short side. Cost to borrow is only 0.56% — shorts are not paying a squeeze premium — but the growing conviction among short sellers is clear.
Options traders read the situation more calmly. The put/call ratio is running at 0.28, noticeably below its 20-day average of 0.32 and close to one standard deviation beneath it. That is meaningfully more call-heavy than usual, suggesting the options market is positioned for an upside outcome from tomorrow's numbers — or at minimum, is not hedging for downside with any particular urgency. The divergence between the growing short position and the relatively bullish options skew is the tension that makes this print interesting.
The Street is constructive but has been trimming ambitions. Oppenheimer maintained its Outperform rating in mid-April but cut its price target from $80 to $65 — a 19% reduction that reflects the same macro caution visible across industrial names. At a current price of $44.33, the consensus mean target around $70 implies roughly 58% upside, though that figure leans on targets set before the tariff-related repricing across industrials this spring. The bull case points to strong EBITDA margins, micro-optic technology leadership, and free cash flow generation. Bears are watching organic sales, which are guided to decline in 2026, alongside rising costs in the international currency business. On valuation, the P/E of 10.0 and EV/EBITDA of 8.1 look compressed, though both have expanded modestly over the past month alongside the 10% price recovery from the April trough. One factor worth flagging: the forward EPS growth rank is in the 80th percentile, a meaningful contrast with the bearish short positioning.
Institutional ownership is stable and tightly held. FMR (Fidelity) is the largest external manager at 14.9%, followed by Vanguard at 10.4% and BlackRock at 7.7%. The Crane Fund, a related entity, holds a further 13.5%. Recent insider activity is unremarkable — award grants followed by same-day tax-withholding sells at the CFO and SVP level through April and May, all at low significance scores. There is no insider buying of note and no net conviction signal worth building a thesis around.
Among correlated peers, KN surged 9.7% on the week and MIR added 7.8%, suggesting broader support for the industrial electronics group. IPGP was the outlier, falling 19% on the week — a reminder that earnings-driven dispersion remains sharp in the sector. CXT ended virtually flat on the week at $44.33, despite the positive peer backdrop, which in itself points to how much uncertainty is being priced around tomorrow's announcement.
The prior print — Q4 results in late February — sent the stock down 4% the next session and 5.8% over the following five days. The Q3 print before that produced a 2% gain. With short interest building into the number, borrow availability tightening toward a year-high, and options traders leaning call-heavy, the direction of tomorrow's reaction is likely to determine which side of that trade is right.
See the live data behind this article on ORTEX.
Open CXT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
